Exact Mass: 463.1622
Exact Mass Matches: 463.1622
Found 500 metabolites which its exact mass value is equals to given mass value 463.1622
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
Pivampicillin
Pivampicillin is only found in individuals that have used or taken this drug. It is an analog of ampicillin.Ampicillin (the active metabolite of pivampicillin) has a bactericidal action resulting from inhibition of cell wall mucopeptide biosynthesis. J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Same as: D08396
Dihydroisomorphine-3-glucuronide
Dihydroisomorphine-3-glucuronide is a metabolite of hydromorphone. Hydromorphone, a more common synonym for dihydromorphinone, commonly a hydrochloride (brand names Palladone, Dilaudid, and numerous others) is a very potent centrally acting analgesic drug of the opioid class. It is a derivative of morphine, to be specific, a hydrogenated ketone thereof and, therefore, a semi-synthetic drug. It is, in medical terms, an opioid analgesic and, in legal terms, a narcotic. (Wikipedia)
Dihydromorphine-3-glucuronide
Dihydromorphine-3-glucuronide is a metabolite of hydromorphone. Hydromorphone, a more common synonym for dihydromorphinone, commonly a hydrochloride (brand names Palladone, Dilaudid, and numerous others) is a very potent centrally acting analgesic drug of the opioid class. It is a derivative of morphine, to be specific, a hydrogenated ketone thereof and, therefore, a semi-synthetic drug. It is, in medical terms, an opioid analgesic and, in legal terms, a narcotic. (Wikipedia)
Etodolac acyl glucuronide
Etodolac acyl glucuronide is a metabolite of etodolac. Etodolac: Etodolac belongs to a class of drugs called nonsteroidal anti-inflammatory drugs. Other members of this class include aspirin, ibuprofen (Motrin, Advil, Nuprin, etc. ), naproxen (Aleve, Naprosyn), indomethacin (Indocin), nabumetone (Relafen) and numerous others. These drugs are used for the management of mild to moderate pain, fever, and inflammation. (Wikipedia)
Rosuvastatin 5 S-lactone
Rosuvastatin 5 S-lactone is a metabolite of rosuvastatin. Rosuvastatin (marketed by AstraZeneca as Crestor) is a member of the drug class of statins, used to treat high cholesterol and related conditions, and to prevent cardiovascular disease. It was developed by Shionogi. (Wikipedia)
Dihydroisomorphine-6-glucuronide
Dihydroisomorphine-6-glucuronide is a metabolite of hydromorphone. Hydromorphone, a more common synonym for dihydromorphinone, commonly a hydrochloride (brand names Palladone, Dilaudid, and numerous others) is a very potent centrally acting analgesic drug of the opioid class. It is a derivative of morphine, to be specific, a hydrogenated ketone thereof and, therefore, a semi-synthetic drug. It is, in medical terms, an opioid analgesic and, in legal terms, a narcotic. (Wikipedia)
(2S,3R)-3-(4-Hydroxyphenyl)-2-(4-{[(2S)-2-pyrrolidin-1-ylpropyl]oxy}phenyl)-2,3-dihydro-1,4-benzoxathiin-6-OL
ent-Rosuvastatin Lactone
1-Methyl-5-(4-benzoyl)pyrrole-2-acetic acid 2-(theophylline-7-yl)ethyl ester
Sipoglitazar
C78276 - Agent Affecting Digestive System or Metabolism > C29711 - Anti-diabetic Agent > C154291 - Peroxisome Proliferator-Activated Receptor Agonist
N-Carbobenzoxyglycyl-prolyl-4-methylcoumarinyl amide
(S)-Phenyl-(tetra-O-acetyl-beta-D-glucopyranosyloxy)-acetonitril|(S)-phenyl-(tetra-O-acetyl-beta-D-glucopyranosyloxy)-acetonitrile|sambunigrin tetraacetate
Lys Ser Asp Asp
Thr Asp Asn Asp
Asp Ser Lys Asp
pivampicillin
J - Antiinfectives for systemic use > J01 - Antibacterials for systemic use > J01C - Beta-lactam antibacterials, penicillins > J01CA - Penicillins with extended spectrum D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D047090 - beta-Lactams D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D010406 - Penicillins D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams C254 - Anti-Infective Agent > C258 - Antibiotic > C260 - Beta-Lactam Antibiotic Same as: D08396
AVE3295
CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4217; ORIGINAL_PRECURSOR_SCAN_NO 4215 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4235; ORIGINAL_PRECURSOR_SCAN_NO 4234 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4218; ORIGINAL_PRECURSOR_SCAN_NO 4217 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4228; ORIGINAL_PRECURSOR_SCAN_NO 4226 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4237; ORIGINAL_PRECURSOR_SCAN_NO 4236 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 4231; ORIGINAL_PRECURSOR_SCAN_NO 4229 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9056; ORIGINAL_PRECURSOR_SCAN_NO 9054 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9059; ORIGINAL_PRECURSOR_SCAN_NO 9057 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9067; ORIGINAL_PRECURSOR_SCAN_NO 9066 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9069; ORIGINAL_PRECURSOR_SCAN_NO 9067 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9087; ORIGINAL_PRECURSOR_SCAN_NO 9082 CONFIDENCE standard compound; INTERNAL_ID 1003; DATASET 20200303_ENTACT_RP_MIX502; DATA_PROCESSING MERGING RMBmix ver. 0.2.7; DATA_PROCESSING PRESCREENING Shinyscreen ver. 0.8.0; ORIGINAL_ACQUISITION_NO 9081; ORIGINAL_PRECURSOR_SCAN_NO 9077
8-2-Amino-3-methylimidazo[4,5-f]quinoline-deoxyguanosine
Ala Cys Asp Arg
Ala Cys Arg Asp
Ala Asp Cys Arg
Ala Asp Met Gln
Ala Asp Gln Met
Ala Asp Arg Cys
Ala Glu Met Asn
Ala Glu Asn Met
Ala Gly Met Trp
Ala Gly Trp Met
Ala Met Asp Gln
Ala Met Glu Asn
Ala Met Gly Trp
Ala Met Asn Glu
Ala Met Gln Asp
Ala Met Trp Gly
Ala Asn Glu Met
Ala Asn Met Glu
Ala Gln Asp Met
Ala Gln Met Asp
Ala Arg Cys Asp
Ala Arg Asp Cys
Ala Trp Gly Met
Ala Trp Met Gly
Cys Ala Asp Arg
Cys Ala Arg Asp
Cys Asp Ala Arg
Cys Asp Ile Asn
Cys Asp Leu Asn
Cys Asp Asn Ile
Cys Asp Asn Leu
Cys Asp Gln Val
Cys Asp Arg Ala
Cys Asp Val Gln
Cys Glu Gly Arg
Cys Glu Asn Val
Cys Glu Arg Gly
Cys Glu Val Asn
Cys Gly Glu Arg
Cys Gly Arg Glu
Cys Gly Val Trp
Cys Gly Trp Val
Cys Ile Asp Asn
Cys Ile Asn Asp
Cys Leu Asp Asn
Cys Leu Asn Asp
Cys Met Asn Pro
Cys Met Pro Asn
Cys Asn Asp Ile
Cys Asn Asp Leu
Cys Asn Glu Val
Cys Asn Ile Asp
Cys Asn Leu Asp
Cys Asn Met Pro
Cys Asn Asn Asn
Cys Asn Pro Met
Cys Asn Val Glu
Cys Pro Met Asn
Cys Pro Asn Met
Cys Gln Asp Val
Cys Gln Val Asp
Cys Arg Ala Asp
Cys Arg Asp Ala
Cys Arg Glu Gly
Cys Arg Gly Glu
Cys Val Asp Gln
Cys Val Glu Asn
Cys Val Gly Trp
Cys Val Asn Glu
Cys Val Gln Asp
Cys Val Trp Gly
Cys Trp Gly Val
Cys Trp Val Gly
Asp Ala Cys Arg
Asp Ala Met Gln
Asp Ala Gln Met
Asp Ala Arg Cys
Asp Cys Ala Arg
Asp Cys Ile Asn
Asp Cys Leu Asn
Asp Cys Asn Ile
Asp Cys Asn Leu
Asp Cys Gln Val
Asp Cys Arg Ala
Asp Cys Val Gln
Asp Asp Asn Thr
Asp Asp Gln Ser
Asp Asp Ser Gln
Asp Asp Thr Asn
Asp Glu Asn Ser
Asp Glu Ser Asn
Asp Gly Ser Trp
Asp Gly Trp Ser
Asp Ile Cys Asn
Asp Ile Asn Cys
Asp Leu Cys Asn
Asp Leu Asn Cys
Asp Met Ala Gln
Asp Met Gln Ala
Asp Asn Cys Ile
Asp Asn Cys Leu
Asp Asn Asp Thr
Asp Asn Glu Ser
Asp Asn Ile Cys
Asp Asn Leu Cys
Asp Asn Ser Glu
Asp Asn Thr Asp
Asp Gln Ala Met
Asp Gln Cys Val
Asp Gln Asp Ser
Asp Gln Met Ala
Asp Gln Ser Asp
Asp Gln Val Cys
Asp Arg Ala Cys
Asp Arg Cys Ala
Asp Ser Asp Gln
Asp Ser Glu Asn
Asp Ser Gly Trp
Asp Ser Asn Glu
Asp Ser Gln Asp
Asp Ser Trp Gly
Asp Thr Asp Asn
Asp Thr Asn Asp
Asp Val Cys Gln
Asp Val Gln Cys
Asp Trp Gly Ser
Asp Trp Ser Gly
Glu Ala Met Asn
Glu Ala Asn Met
Glu Cys Gly Arg
Glu Cys Asn Val
Glu Cys Arg Gly
Glu Cys Val Asn
Glu Asp Asn Ser
Glu Asp Ser Asn
Glu Gly Cys Arg
Glu Gly Met Gln
Glu Gly Gln Met
Glu Gly Arg Cys
Glu Met Ala Asn
Glu Met Gly Gln
Glu Met Asn Ala
Glu Met Gln Gly
Glu Asn Ala Met
Glu Asn Cys Val
Glu Asn Asp Ser
Glu Asn Met Ala
Glu Asn Ser Asp
Glu Asn Val Cys
Glu Gln Gly Met
Glu Gln Met Gly
Glu Arg Cys Gly
Glu Arg Gly Cys
Glu Ser Asp Asn
Glu Ser Asn Asp
Glu Val Cys Asn
Glu Val Asn Cys
Gly Ala Met Trp
Gly Ala Trp Met
Gly Cys Glu Arg
Gly Cys Arg Glu
Gly Cys Val Trp
Gly Cys Trp Val
Gly Asp Ser Trp
Gly Asp Trp Ser
Gly Glu Cys Arg
Gly Glu Met Gln
Gly Glu Gln Met
Gly Glu Arg Cys
Gly Met Ala Trp
Gly Met Glu Gln
Gly Met Gln Glu
Gly Met Trp Ala
Gly Gln Glu Met
Gly Gln Met Glu
Gly Arg Cys Glu
Gly Arg Glu Cys
Gly Ser Asp Trp
Gly Ser Trp Asp
Gly Val Cys Trp
Gly Val Trp Cys
Gly Trp Ala Met
Gly Trp Cys Val
Gly Trp Asp Ser
Gly Trp Met Ala
Gly Trp Ser Asp
Gly Trp Val Cys
Ile Cys Asp Asn
Ile Cys Asn Asp
Ile Asp Cys Asn
Ile Asp Asn Cys
Ile Asn Cys Asp
Ile Asn Asp Cys
Leu Cys Asp Asn
Leu Cys Asn Asp
Leu Asp Cys Asn
Leu Asp Asn Cys
Leu Asn Cys Asp
Leu Asn Asp Cys
Met Ala Asp Gln
Met Ala Glu Asn
Met Ala Gly Trp
Met Ala Asn Glu
Met Ala Gln Asp
Met Ala Trp Gly
Met Cys Asn Pro
Met Cys Pro Asn
Met Asp Ala Gln
Met Asp Gln Ala
Met Glu Ala Asn
Met Glu Gly Gln
Met Glu Asn Ala
Met Glu Gln Gly
Met Gly Ala Trp
Met Gly Glu Gln
Met Gly Gln Glu
Met Gly Trp Ala
Met Asn Ala Glu
Met Asn Cys Pro
Met Asn Glu Ala
Met Asn Pro Cys
Met Pro Cys Asn
Met Pro Asn Cys
Met Gln Ala Asp
Met Gln Asp Ala
Met Gln Glu Gly
Met Gln Gly Glu
Met Trp Ala Gly
Met Trp Gly Ala
Asn Ala Glu Met
Asn Ala Met Glu
Asn Cys Asp Ile
Asn Cys Asp Leu
Asn Cys Glu Val
Asn Cys Ile Asp
Asn Cys Leu Asp
Asn Cys Met Pro
Asn Cys Asn Asn
Asn Cys Pro Met
Asn Cys Val Glu
Asn Asp Cys Ile
Asn Asp Cys Leu
Asn Asp Asp Thr
Asn Asp Glu Ser
Asn Asp Ile Cys
Asn Asp Leu Cys
Asn Asp Ser Glu
Asn Asp Thr Asp
Asn Glu Ala Met
Asn Glu Cys Val
Asn Glu Asp Ser
Asn Glu Met Ala
Asn Glu Ser Asp
Asn Glu Val Cys
Asn Ile Cys Asp
Asn Ile Asp Cys
Asn Leu Cys Asp
Asn Leu Asp Cys
Asn Met Ala Glu
Asn Met Cys Pro
Asn Met Glu Ala
Asn Met Pro Cys
Asn Asn Cys Asn
Asn Asn Asn Cys
Asn Pro Cys Met
Asn Pro Met Cys
Asn Ser Asp Glu
Asn Ser Glu Asp
Asn Thr Asp Asp
Asn Val Cys Glu
Asn Val Glu Cys
Pro Cys Met Asn
Pro Cys Asn Met
Pro Met Cys Asn
Pro Met Asn Cys
Pro Asn Cys Met
Pro Asn Met Cys
Gln Ala Asp Met
Gln Ala Met Asp
Gln Cys Asp Val
Gln Cys Val Asp
Gln Asp Ala Met
Gln Asp Cys Val
Gln Asp Asp Ser
Gln Asp Met Ala
Gln Asp Ser Asp
Gln Asp Val Cys
Gln Glu Gly Met
Gln Glu Met Gly
Gln Gly Glu Met
Gln Gly Met Glu
Gln Met Ala Asp
Gln Met Asp Ala
Gln Met Glu Gly
Gln Met Gly Glu
Gln Ser Asp Asp
Gln Val Cys Asp
Gln Val Asp Cys
Arg Ala Cys Asp
Arg Ala Asp Cys
Arg Cys Ala Asp
Arg Cys Asp Ala
Arg Cys Glu Gly
Arg Cys Gly Glu
Arg Asp Ala Cys
Arg Asp Cys Ala
Arg Glu Cys Gly
Arg Glu Gly Cys
Arg Gly Cys Glu
Arg Gly Glu Cys
Ser Asp Asp Gln
Ser Asp Glu Asn
Ser Asp Gly Trp
Ser Asp Asn Glu
Ser Asp Gln Asp
Ser Asp Trp Gly
Ser Glu Asp Asn
Ser Glu Asn Asp
Ser Gly Asp Trp
Ser Gly Trp Asp
Ser Asn Asp Glu
Ser Asn Glu Asp
Ser Gln Asp Asp
Ser Trp Asp Gly
Ser Trp Gly Asp
Thr Asp Asp Asn
Thr Asn Asp Asp
Val Cys Asp Gln
Val Cys Glu Asn
Val Cys Gly Trp
Val Cys Asn Glu
Val Cys Gln Asp
Val Cys Trp Gly
Val Asp Cys Gln
Val Asp Gln Cys
Val Glu Cys Asn
Val Glu Asn Cys
Val Gly Cys Trp
Val Gly Trp Cys
Val Asn Cys Glu
Val Asn Glu Cys
Val Gln Cys Asp
Val Gln Asp Cys
Val Trp Cys Gly
Val Trp Gly Cys
Trp Ala Gly Met
Trp Ala Met Gly
Trp Cys Gly Val
Trp Cys Val Gly
Trp Asp Gly Ser
Trp Asp Ser Gly
Trp Gly Ala Met
Trp Gly Cys Val
Trp Gly Asp Ser
Trp Gly Met Ala
Trp Gly Ser Asp
Trp Gly Val Cys
Trp Met Ala Gly
Trp Met Gly Ala
Trp Ser Asp Gly
Trp Ser Gly Asp
Trp Val Cys Gly
Trp Val Gly Cys
4-[(5-Amino-1-methyl-1H-indol-3-yl)methyl]-3-methoxy-N-[(2-methylphenyl)sulfonyl]benzamide
Moricizine hydrochloride
D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers C78274 - Agent Affecting Cardiovascular System > C47793 - Antiarrhythmic Agent D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators C93038 - Cation Channel Blocker
3-[[9,10-dihydro-4-(methylamino)-9,10-dioxo-1-anthryl]aminopropyl]trimethylammonium methyl sulphate
1-((4-CHLOROPHENYL)SULFONYL)-4-(5-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PYRIDIN-2-YL)PIPERAZINE
2-ethoxyethyl [2-[(2-chloro-4-nitrophenyl)azo]-5-(diethylamino)phenyl]carbamate
N-(6-Methoxy-3-pyridinyl)-1,2-dimethyl-N-{[5-(2-methylphenyl)-2-p yridinyl]methyl}-1H-imidazole-4-sulfonamide
(2R,5S,13aR)-8-methoxy-7,9-dioxo-N-(2,4,6-trifluorobenzyl)-2,3,4,5,7,9,13,13a-octahydro-2,5-methanopyrido[1,2:4,5]pyrazino[2,1-b][1,3]oxazepine-10-carboxamide
Pelitrexol
C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C272 - Antimetabolite C471 - Enzyme Inhibitor > C2692 - Glycinamide Ribonucleotide Formyltransferase Inhibitor
Berzosertib
C274 - Antineoplastic Agent > C2189 - Signal Transduction Inhibitor > C129824 - Antineoplastic Protein Inhibitor C471 - Enzyme Inhibitor > C1404 - Protein Kinase Inhibitor > C61074 - Serine/Threonine Kinase Inhibitor C471 - Enzyme Inhibitor > C129825 - Antineoplastic Enzyme Inhibitor
5-Fluoro-N-((1S)-1-phenylpropyl)-2-((quinolin-8-ylsulfonyl)amino)benzamide
(2S,3R)-2-(4-(2-(Piperidin-1-YL)ethoxy)phenyl)-2,3-dihydro-3-(4-hydroxyphenyl)benzo[B][1,4]oxathiin-6-OL
(2S,3R)-3-(4-Hydroxyphenyl)-2-(4-{[(2S)-2-pyrrolidin-1-ylpropyl]oxy}phenyl)-2,3-dihydro-1,4-benzoxathiin-6-OL
(2S,3R)-3-(4-Hydroxyphenyl)-2-(4-{[(2R)-2-pyrrolidin-1-ylpropyl]oxy}phenyl)-2,3-dihydro-1,4-benzoxathiin-6-OL
1-[2-[5-[(3-Amino-3-carboxypropyl)amino]-3-carboxy-3-hydroxy-5-oxopentanoyl]oxyethyl]-2-hydroxy-5-oxopyrrolidine-2-carboxylic acid
1-[3-[[5-(2-Aminoethoxy)-3-carboxy-3-hydroxy-5-oxopentanoyl]amino]-1-carboxypropyl]-2-hydroxy-5-oxopyrrolidine-2-carboxylic acid
4-(3-{2-[(ethoxycarbonyl)amino]-10H-phenothiazin-10-yl}-3-oxopropyl)morpholin-4-ium chloride
D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers > D061567 - Voltage-Gated Sodium Channel Blockers D002317 - Cardiovascular Agents > D000889 - Anti-Arrhythmia Agents D049990 - Membrane Transport Modulators
1-[2-[[[2-Chloro-4-(trifluoromethyl)anilino]-oxomethyl]amino]-2-methyl-1-oxopropyl]-4-piperidinecarboxylic acid ethyl ester
2-Ethoxy-3-pyridinecarboxylic acid [2-[2-methyl-5-(4-morpholinylsulfonyl)anilino]-2-oxoethyl] ester
(E)-3-[9-methyl-2-(4-methylpiperazin-1-yl)-4-oxopyrido[1,2-a]pyrimidin-3-yl]-2-(4-methylphenyl)sulfonylprop-2-enenitrile
N-(1,3-benzodioxol-5-ylmethyl)-N-[2-(cyclohexylamino)-2-oxo-1-pyridin-4-ylethyl]-2,2,2-trifluoroacetamide
3-[2-[1-(4-methoxyphenyl)-2,5-dimethyl-3-pyrrolyl]-2-oxoethyl]spiro[6,7-dihydro-5H-1-benzothiophene-4,5-imidazolidine]-2,4-dione
3-[(3aR,4S,9bR)-1-(4-fluorophenyl)sulfonyl-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-4-methoxy-N-methylbenzenesulfonamide
3-[(3aS,4S,9bS)-1-(4-fluorophenyl)sulfonyl-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
1-[(2S,3S,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3R,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2S,3R,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)oxan-3-yl]-3-(2-methoxyphenyl)urea
[(2R,4R)-4-(1-benzothiophen-3-yl)-2-[[4-(hydroxymethyl)phenyl]methoxy]-3,4-dihydro-2H-pyran-6-yl]-(1-piperidinyl)methanone
1-[(2S,3S,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
N-[2-[(2S,5R,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2R,5R,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2S,5R,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
3-[(3aS,4R,9bS)-1-(4-fluorophenyl)sulfonyl-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
(6R,7S,8S)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8R)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7S,8R)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
1-[(2S,3R,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3S,6R)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3S,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
1-[(2R,3R,6S)-6-[2-(benzenesulfonamido)ethyl]-2-(hydroxymethyl)-3-oxanyl]-3-(2-methoxyphenyl)urea
N-[2-[(2R,5S,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2S,5S,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2R,5R,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2S,5S,6R)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
N-[2-[(2R,5S,6S)-6-(hydroxymethyl)-5-[(4-methoxyphenyl)sulfonylamino]-2-oxanyl]ethyl]-2-(2-pyridinyl)acetamide
3-[(3aR,4R,9bR)-1-(4-fluorophenyl)sulfonyl-4-(hydroxymethyl)-2,3,3a,4,5,9b-hexahydropyrrolo[3,2-c]quinolin-8-yl]benzonitrile
(6R,7R,8S)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6R,7R,8R)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8R)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7R,8S)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
(6S,7S,8S)-N-(4-fluorophenyl)-7-[4-(3-fluorophenyl)phenyl]-8-(hydroxymethyl)-2-oxo-1,4-diazabicyclo[4.2.0]octane-4-carboxamide
2,2-dimethylpropanoyloxymethyl (2S,5S,6R)-6-[[(2R)-2-amino-2-phenylacetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylate
N-(3-chloro-4-fluorophenyl)-6-[3-(4-hydroxymorpholin-4-ium-4-yl)propoxy]-7-methoxyquinazolin-4-amine
ERK1/2 inhibitor 7
ERK1/2 inhibitor 7 is a potent ERK inhibitor with an IC50 of 0.94 nM for ERK2 (WO2021110168A1, WX006)[1].
MGL-IN-1
MGL-IN-1 is a potent and selective irreversible MGL (β-lactam-based monoacylglycerol lipase) inhibitor. MGL-IN-1 alleviates symptoms in a MS model in vivo and exhibits analgesic effects in an acute inflammatory pain model in vivo. MGL-IN-1 displays high membrane permeability and brain penetrant[1].
SM1-71
SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines[1][2][3].